From the Wires
immatics Appoints Peter Chambré as Chairman
Nov. 12, 2012 03:01 AM
TUEBINGEN, Germany, November 12, 2012 /PRNewswire/ --
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has been Chairman of the Company since 2004.
Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006. Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company.
Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions. From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012, Non-executive Director of BTG plc. Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies.
Paul Higham, CEO of immatics, said: "I am delighted to welcome Peter as our new Chairman. We are approaching a crucial period at immatics, and Peter's experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximize returns to our investors."
Peter Chambré said: "immatics' vaccines, based on the Company's highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials. With IMA901, immatics' lead multi-peptide based vaccine now in phase 3 development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company. On behalf of immatics, I would like to express my thanks to Thomas Widmann for his very significant contribution to the development of the Company over the past 8 years. I very much look forward to working with the Board and management, as immatics aims to improve outcomes for cancer patients and create value for all its stakeholders."
For additional information on immatics please visit http://www.immatics.com or contact:
About immatics
immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer. immatics' lead product, IMA901, is in a pivotal phase 3 study after completing a successful randomized phase 2 trial in renal cell carcinoma. immatics' pipeline also includes IMA910, which has reported improved overall survival data in patients with advanced colorectal cancer (phase 1/2 study completed), and IMA950, which is in phase 1 in patients with glioma.
immatics' unique technology platform XPRESIDENT[TM] discovers novel relevant cancer antigens known to be expressed on tumor cells, tumor-associated peptides (TUMAPs), as the basis for its vaccines. In contrast to widely used existing in silico and indirect methods to identify peptide antigens immatics' TUMAPs are confirmed to be naturally expressed in primary cancer tissue. TUMAPs activate white blood cells (so called cytotoxic T cells) against tumor cells.
immatics' vaccines contain multiple TUMAPs to maximize the chances of clinical success by increasing the number of targets on cancer cells that they address. Phase 2 results with IMA901 and IMA910 have shown significantly better survival in patients who respond to multiple TUMAPs in both of these vaccines.
immatics' multi-peptide vaccines are 'drug like', i.e. fully synthetic, off-the-shelf, easily scalable and stable.
immatics is based in Tuebingen and Martinsried (Munich), Germany.
Paul Higham, CEO
Dr. Nikola Wiegeler, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49-7071-5397-110
E-mail: media@immatics.com
Citigate Dewe Rogerson
David Dible / Chris Gardner / Sita Shah
Phone: +44(0)207-638-9571
E-mail: david.dible@citigatedr.co.uk
About PR NewswireCopyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
.gif)
Organizations across the world are increasingly starting to see the benefits of moving more and more services to the cloud. The focus on the cost-saving potential of cloud is rapidly shifting to completely transforming the business with cloud. As organizations are investing enorm...
Storage and Archive offerings are now exploding on the market. From end-user mobile devices to company tactical level, the cloud has become a black hole for every kind of data. But what are the risks, and what are the real needs?
In his session at the 12th International Cloud E...
These days, it seems that every cloud provider claims that cloud is safer than your traditional datacenter. Is it though? In his General Session at 12th Cloud Expo | Cloud Expo New York, McAfee expert Rishi Bhargava will help you explore and address the security challenges and co...
Companies around the world are collecting massive amounts of data everyday that’s sitting around and not being utilized. Take for example the fact that companies collect demographic and location-based data via mobile devices all the time, but have to figure out how to monetize th...
At pennies per virtual machine-hour, the economics of cloud computing are both compelling and daunting to replicate. Whether you are building your own cloud infrastructure, building a public cloud or choosing a cloud service, there are key strategy and technology decisions that m...
